GuangYuYuan Chinese Herbal Medicine Co (600771) Fair Value & Analysis
Healthcare · CN · Market cap 7.0B CNY
Fair value as of: Aug 9, 2026
From 26 valuation models · updated yesterday
Share price +2.3% over the past month.
A solid business, but screening 80% overvalued on our models.
What matters now
- A high-quality business (quality 70/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- The price sits above even our optimistic bull case (¥3.54). The favourable scenario is already priced in.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 9, 2026.
How to read this chart
60‑month range ¥12.71 – ¥53.35 · fair‑value band ¥2.13 – ¥3.54 · the ¥14.29 price screens above the ¥2.83 fair value. Dashed = 300-day average. As of Aug 9, 2026.
Analysis
GuangYuYuan Chinese Herbal Medicine Co (600771) currently trades at ¥14.29, while our model-based Fair Value estimate is ¥2.83, implying the stock looks roughly 80.2% overvalued today. The Quality Score stands at 70/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, GuangYuYuan Chinese Herbal Medicine Co generated revenue of 1.4B CNY at a net margin of 4.6%. Revenue grew 17.0% year over year. It earns a return on equity of 4.0%. The balance sheet holds a net cash position of 62.9M CNY. Fundamentals as of Aug 9, 2026
Our scenario range runs from ¥2.13 (bear case) to ¥3.54 (bull case); at ¥14.29, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 38% below its 52-week high and 6% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -25% fair-value upside, at -80%, 600771 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (¥5.46) versus Dividend Discount (¥0.0400). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 9, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 70 · Market factors (momentum, volatility) 35
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
GuangYuYuan Chinese Herbal Medicine Co., Ltd. manufactures and sells Chinese medicinal products. The company offers traditional Chinese medicine, fine Chinese medicine, and health wine. It provides its products in the form of pills, powders, tablets, hard capsules, granules, mixtures, and wine preparations.
Full company description
GuangYuYuan Chinese Herbal Medicine Co., Ltd. manufactures and sells Chinese medicinal products. The company offers traditional Chinese medicine, fine Chinese medicine, and health wine. It provides its products in the form of pills, powders, tablets, hard capsules, granules, mixtures, and wine preparations. The company was formerly known as Topsun Science And Technology Co Ltd. and changed its name to GuangYuYuan Chinese Herbal Medicine Co., Ltd. in July 2013. GuangYuYuan Chinese Herbal Medicine Co., Ltd. was founded in 1996 and is headquartered in Taiyuan, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
GuangYuYuan Chinese Herbal Medicine Co reported revenue of ¥1.4B in FY2025 versus ¥854M in FY2021, a compound +12.5%/yr. Reported net income was ¥63.0M in FY2025.
600771 screens 80% overvalued. Compare with Eli Lilly and Company →
Peer Group
Drug Manufacturers - General · 76 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - General median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Aug 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,182 | $396.77 | -66% |
| Johnson & Johnson, JNJ | $257.59 | $169.04 | -34% |
| AbbVie Inc ABBV | $254.49 | $67.72 | -73% |
| Roche Holding 1RO | €392.80 | €226.68 | -42% |
| Merck & Co MRK | €108.08 | €121.54 | +12% |
| Novartis AG NVSN | 2,742 MXN | 2,379 MXN | -13% |
| AstraZeneca PLC AZN | $171.61 | $129.54 | -25% |
| Novo Nordisk A/S NOVOB | kr 329.90 | kr 409.46 | +24% |
| Amgen Inc AMGN | $363.39 | $252.02 | -31% |
| Sanofi SNYN | 770.00 MXN | 1,251 MXN | +63% |
Compare GuangYuYuan Chinese Herbal Medicine Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is GuangYuYuan Chinese Herbal Medicine Co (600771) overvalued or undervalued?
What is the fair value of 600771?
What is the quality score of 600771?
What is the revenue of GuangYuYuan Chinese Herbal Medicine Co (600771)?
What is the net profit margin of 600771?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track GuangYuYuan Chinese Herbal Medicine Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.